Finance

Lists
Q3 2026 earnings • released • Revenue beat +60,42%
See results
GLUE:NASDAQ
Monte Rosa Therapeutics Inc
10,25 USD
-5,27%
(-0,57) 1D
5-ноя., 15:53:04 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GLUE...
Open
10,48 USD
High
10,58 USD
Low
10,14 USD
Mkt. cap
874,46 млн
Avg. vol.
1,49 млн
Volume
843,07 миң
52-wk high
25,77 USD
52-wk low
9,68 USD
EPS
-1,74 USD
Beta
1,41
Shares outstanding
85,31 млн
No. of employees
173
Open
10,48 USD
High
10,58 USD
Low
10,14 USD
Mkt. cap
874,46 млн
Avg. vol.
1,49 млн
Volume
843,07 миң
52-wk high
25,77 USD
52-wk low
9,68 USD
EPS
-1,74 USD
Beta
1,41
Shares outstanding
85,31 млн
No. of employees
173
News stories
From web sources and news partners
About Monte Rosa Therapeutics Inc
CEO-
Employees173
Founded2019
HeadquartersБостон, Массачусетс, Америка Кошмо Штаттары
SectorHealth Care
Industry-
Websitemonterosatx.com
Analyst ratings
Based on 7 analysts giving stock ratings to GLUE in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for GLUE in the last 3 months.
Highest
Current 10,25 USD
37,00 USD (+260,98%)
Average
27,17 USD (+165,07%)
Lowest
19,00 USD (+85,37%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
UBS
Buy
Reiterated
19,00 USD
+85,4%
10/12/2026
Alice Nettleton
UBS
Buy
Initiated
19,00 USD
+85,4%
10/12/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
25,00 USD
+143,9%
10/05/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
-
-
10/02/2026
Robert Driscoll
Wedbush
Buy
Maintained
27,00 USD
+163,4%
10/02/2026
Unknown Analyst
Wedbush
Buy
Maintained
27,00 USD
+163,4%
10/02/2026
Michael Schmidt
Guggenheim
Buy
Maintained
28,00 USD
+173,2%
10/01/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
37,00 USD
+261%
10/02/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
27,00 USD
+163,4%
08/10/2026
Faisal Khurshid
Jefferies
Buy
Maintained
25,00 USD
+143,9%
07/31/2026
Derek Archila
Wells Fargo
Buy
Reiterated
29,00 USD
+182,9%
06/24/2026
Marc Frahm
TD Cowen
Buy
Reiterated
-
-
05/07/2026
Last report
Just released
Today, 14:00
Fiscal period
Q3 2026
- / -0,20 USD
Revenue / Est. (USD)
54,37 млн / 33,89 млн
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
12,77 млн
2,78 млн
4,21 млн
8,97 млн
Cost of goods sold
34,65 млн
39,89 млн
41,82 млн
45,99 млн
Cost of revenue
34,65 млн
39,89 млн
41,82 млн
45,99 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11,09 млн
12,60 млн
12,42 млн
12,11 млн
Operating expense
11,09 млн
12,60 млн
12,42 млн
12,11 млн
Total operating expenses
45,74 млн
52,50 млн
54,24 млн
58,10 млн
Operating income
-32,98 млн
-49,72 млн
-50,03 млн
-49,13 млн
Other non operating income
-
-
-
-
EBT including unusual items
-30,26 млн
-46,08 млн
-44,45 млн
-43,19 млн
EBT excluding unusual items
-30,26 млн
-46,08 млн
-44,45 млн
-43,19 млн
Income tax expense
-3,18 млн
59,00 миң
52,00 миң
208,00 миң
Effective tax rate
10,50%
-0,13%
-0,12%
-0,48%
Other operating expenses
-
-
-
-
Net income
-27,08 млн
-46,14 млн
-44,50 млн
-43,40 млн
Net profit margin
-212,10%
-1 658,94%
-1 057,08%
-483,91%
Earnings per share
-0,33
-0,55
-0,45
-0,43
Interest and investment income
2,75 млн
3,69 млн
5,59 млн
5,92 млн
Interest expense
-
-
-
-
Net interest expenses
2,75 млн
3,69 млн
5,59 млн
5,92 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-30,88 млн
-47,63 млн
-48,00 млн
-47,22 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору